Authors/Disclosures
|
Diana M. Escolar, MD, FAAN
|
No disclosure on file |
|
Dhairyawan Pokalkar, MD, FAAN
(MD Neuro Care)
|
No disclosure on file |
|
Ksenija Gorni
|
Dr. Gorni has received personal compensation for serving as an employee of Hoffman La Roche. |
|
|
No disclosure on file |
|
Jean K. Mah, MD, FRCPC, FAAN
(University of Calgary)
|
Dr. Mah has nothing to disclose. |
|
Yoram Nevo, MD
(Schneider Children'S Medical Center of Israel)
|
No disclosure on file |
|
Andrew J. Kornberg, MD
(Royal Childrens Hospital)
|
Dr. Kornberg has nothing to disclose. |
|
Hanna Kolski, MD
|
No disclosure on file |
|
Tulio E. Bertorini, MD
(Semmes Murphey Clinic)
|
Dr. Bertorini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Bertorini has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Bertorini has received publishing royalties from a publication relating to health care. |
|
Anne M. Connolly, MD, FAAN
(Nationwide Children's Hospital)
|
Dr. Connolly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Edgewise Therapeutics. Dr. Connolly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Octapharma. Dr. Connolly has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Connolly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. The institution of Dr. Connolly has received research support from Muscular Dystrophy Association. The institution of Dr. Connolly has received research support from NIH. |
|
Nancy L. Kuntz, MD, FAAN
(Ann & Robert H Lurie Children'S Hospital of Chicago)
|
Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenyx. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Audentes Therapeutics. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kuntz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. The institution of Dr. Kuntz has received research support from Argenx. The institution of Dr. Kuntz has received research support from Astellas. The institution of Dr. Kuntz has received research support from Biogen. The institution of Dr. Kuntz has received research support from Catalyst. The institution of Dr. Kuntz has received research support from Genentech. The institution of Dr. Kuntz has received research support from Scholar Rock. The institution of Dr. Kuntz has received research support from Regenx-Bio. The institution of Dr. Kuntz has received research support from Solid Biosciences. The institution of Dr. Kuntz has received research support from AMO. The institution of Dr. Kuntz has received research support from Novartis. The institution of Dr. Kuntz has received research support from BioHaven. Dr. Kuntz has received personal compensation in the range of $50,000-$99,999 for serving as a Sarepta Express post gene therapy advisor with Sarepta. |
|
|
No disclosure on file |
|
Paula R. Clemens, MD
(Univ of Pittsburgh/ Dept of Neurology)
|
The institution of Dr. Clemens has received research support from NS Pharma. The institution of Dr. Clemens has received research support from ReveraGen. The institution of Dr. Clemens has received research support from Amicus. The institution of Dr. Clemens has received research support from Sanofi. The institution of Dr. Clemens has received research support from Spark. The institution of Dr. Clemens has received research support from NIH. The institution of Dr. Clemens has received research support from MDA. The institution of Dr. Clemens has received research support from FDA. |
|
|
No disclosure on file |
|
Lauren Morgenroth
(TRiNDS, LLC)
|
Ms. Morgenroth has received personal compensation for serving as an employee of TRiNDS. Ms. Morgenroth has stock in TRiNDS. |
|
|
No disclosure on file |
|
Julaine M. Florence
(Washington University)
|
Ms. Florence has nothing to disclose. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Erik K. Henricson, MPH
(University of California Davis)
|
No disclosure on file |
|
Robert T. Leshner, MD, FAAN
(University of California San Diegp)
|
No disclosure on file |
|
Alberto L. Dubrovsky, MD
|
No disclosure on file |